Get in touch
Our Client Services team is on hand to help. Please call us at 866.776.5907, Option 3.
This panel is designed to detect key genetic alterations associated with acute myeloid leukemia (AML) through next-generation sequencing (NGS). It includes the following genes:
DNA NGS (SNV/Indel):
ASXL1, BCOR, BRAF, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2, KIT, KMT2A (MLL), KRAS, NPM1, NRAS, PDGFRA, PHF6, PML, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2
Test Customization: FLT3 by PCR (via FLT3 Mutation Analysis) is available for concurrent testing as a Client-Bill option. It is reported separately to support prompt therapy selection in newly diagnosed AML cases.
Test Recommendations: For patients with therapy-related AML, AML that evolved from MDS, and AML with myelodysplasia, the NeoTYPE® MDS/CMML Profile is recommended.
Bone Marrow Aspirate: 2 mL in EDTA tube. Sodium heparin is acceptable.
Peripheral Blood: 5 mL in EDTA tube. Sodium heparin is acceptable.
H&E slide (required) plus paraffin block.
Cut Slides: H&E slide (required) plus 10-14 unstained slides cut at 5+ microns.
Note on FFPE: Paraffin block is preferred. Do not use zinc fixatives. If submitting slides, please use positively-charged slides and 10% NBF fixative. Block and slide identifiers should be clearly written and match exactly with the specimen ID and specimen labeling as noted on the requisition.
Do not use mercury fixatives (B5). Highly acidic or prolonged decalcification processes will not yield sufficient nucleic acid to accurately perform molecular studies.
Note: Test is TNA-based. Please select Extract & Hold - TNA If specimen hold service is desired.
81450x1
*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
Last Updated: August 05, 2025